David A Rizzieri

David A Rizzieri

UNVERIFIED PROFILE

Are you David A Rizzieri?   Register this Author

Register author
David A Rizzieri

David A Rizzieri

Publications by authors named "David A Rizzieri"

Are you David A Rizzieri?   Register this Author

89Publications

2783Reads

40Profile Views

Targeting High Mobility Group Box-1 (HMGB1) Promotes Cell Death in Myelodysplastic Syndrome.

Clin Cancer Res 2019 Jul 5;25(13):4155-4167. Epub 2019 Apr 5.

Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3517DOI Listing
July 2019

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

N Engl J Med 2019 04;380(17):1628-1637

From the University of Texas M.D. Anderson Cancer Center, Houston (N.P., M.D., H.M.K., M.K.); Dana-Farber Cancer Institute (A.A.L.) and Boston University School of Medicine (J.M.S.), Boston, and Veristat, Southborough (J.B.) - all in Massachusetts; H. Lee Moffitt Cancer Center, Tampa, FL (K.L.S., J.E.L.); City of Hope National Medical Center, Duarte, CA (A.S.S.); Ohio State University, Columbus (S.V.); Winship Cancer Institute of Emory University, Atlanta (W.B.); Duke University Medical Center, Durham, NC (D.A.R.); and Roswell Park Comprehensive Cancer Center, Buffalo (E.S.W.), and Stemline Therapeutics, New York (S. Spence, S. Shemesh, C.L.B., I.B.) - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1815105DOI Listing
April 2019

Treatment of blastic plasmacytoid dendritic cell neoplasm.

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):16-23

Duke Cancer Institute, Durham, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.16DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142460PMC
December 2016

Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy.

Eur J Haematol 2016 Oct 31;97(4):313-20. Epub 2016 May 31.

Division of Hematologic Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12771DOI Listing
October 2016

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.

Adv Radiat Oncol 2016 Oct-Dec;1(4):272-280. Epub 2016 Jul 15.

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2016.07.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514157PMC
July 2016

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

J Clin Oncol 2016 06 4;34(16):1864-71. Epub 2016 Apr 4.

Brian C. Shaffer and Martin Tallman, Memorial Sloan Kettering Cancer Center; Adriana K. Malone, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai; Ran Reshef, Columbia University Medical Center, New York; Mark Litzow, Mayo Clinic Rochester; Jane Liesveld, University of Rochester Medical Center, Rochester; Peter H. Wiernik, Our Lady of Mercy Medical Center, Bronx, NY; Kwang Woo Ahn, Zhen-Huan Hu, and Wael Saber, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Taiga Nishihori and Mohamed A. Kharfan-Dabaja, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David Valcárcel, Hospital Vall d'Hebron, Barcelona, Spain; Michael R. Grunwald, Omotayo Fasan, and Edward Copelan, Levine Cancer Institute, Carolinas HealthCare System, Charlotte; William Allen Wood, University of North Carolina at Chapel Hill, Chapel Hill; David A. Rizzieri, Duke University Medical Center, Durham, NC; Ulrike Bacher, University of Medicine Göttingen, Göttingen, Germany; Betty Hamilton and Aaron Gerds, Cleveland Clinic Taussig Cancer Institute; Matt Kalaycio and Ron Sobecks, Cleveland Clinic Foundation, Cleveland; Basem William, Ohio State University Medical Center, Columbus, OH; Ayman Saad and Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Corey Cutler and Edwin Alyea, Dana-Farber Cancer Institute, Boston, MA; Erica Warlick and Celalettin Ustun, University of Minnesota Medical Center, Minneapolis, MN; Baldeep Mona Wirk, Seattle Cancer Care Alliance, Seattle, WA; Mitchell Sabloff, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario; Andrew Daly, Tom Baker Cancer Center, Calgary, Alberta, Canada; David Marks, University Hospitals Bristol National Health Service Trust, Bristol; Robert Peter Gale, Imperial College London, London, United Kingdom; Richard Olsson, Karolinska Institutet, Stockholm, Sweden; Alan M. Miller, Baylor University Medical Center; Rammurti Kamble

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966345PMC
June 2016

Clinical potential of elacytarabine in patients with acute myeloid leukemia.

Ther Adv Hematol 2014 Dec;5(6):211-20

Duke University Medical Center - Medicine, 1149 North Pavilion Duke University Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620714552615DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250268PMC
December 2014

Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.

Biol Blood Marrow Transplant 2014 Feb 20;20(2):257-63. Epub 2013 Nov 20.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.11.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140655PMC
February 2014

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

J Clin Oncol 2014 Feb 16;32(4):273-81. Epub 2013 Dec 16.

Timothy S. Fenske and Mehdi Hamadani, Medical College of Wisconsin; Mei-Jie Zhang, Jeanette Carreras, and Parameswaran N. Hari, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; Ernesto Ayala, H. Lee Moffitt Cancer Center and Research Institute, Tampa; Baldeep M. Wirk, Shands Healthcare and University of Florida, Gainesville, FL; Linda J. Burns, University of Minnesota Medical Center, Fairview, Minneapolis; David J. Inwards, Mayo Clinic Rochester, Rochester, MN; Amanda Cashen, Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO; Luciano J. Costa, Medical University of South Carolina, Charleston, SC; César O. Freytes, South Texas Veterans Health Care System and University of Texas Health Science Center, San Antonio, TX; Robert P. Gale, Imperial College; Silvia Montoto, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Leona A. Holmberg and David G. Maloney, Fred Hutchinson Cancer Research Center, Seattle, WA; Hillard M. Lazarus, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH; Richard T. Maziarz, Oregon Health and Science University, Portland, OR; Reinhold Munker, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA; Miguel-Angel Perales, Memorial Sloan-Kettering Cancer Center, New York, NY; David A. Rizzieri, Duke University Medical Center, Durham, NC; Harry C. Schouten, Academische Ziekenhuis Maastricht, Maastricht, the Netherlands; Sonali M. Smith, University of Chicago Hospitals, Chicago, IL; Edmund K. Waller, Emory University Hospital, Atlanta, GA; and Ginna G. Laport, Stanford Hospital and Clinics, Stanford, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2454DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897255PMC
February 2014

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.

J Clin Oncol 2013 Nov 14;31(33):4199-206. Epub 2013 Oct 14.

Philippe Armand and Edie Weller, Dana-Farber Cancer Institute; David E. Avigan, Beth Israel Deaconess Medical Center; Yi-Bin Chen, Massachusetts General Hospital, Boston, MA; Arnon Nagler, Chaim Sheba Medical Center, Tel-Hashomer; Reuven Or, Hadassah Medical Center, Jerusalem; Rinat Rotem-Yehudar, CureTech, Yavne, Israel; Steven M. Devine, The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus; Hillard M. Lazarus, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Mark S. Kaminski, University of Michigan, Ann Arbor, MI; H. Kent Holland, Northside Hospital; Edmund K. Waller, Winship Cancer Institute, Emory University, Atlanta, GA; Jane N. Winter and Leo I. Gordon, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine; Stephanie A. Gregory, Rush Medical Center, Chicago, IL; James R. Mason, Scripps Clinic; Edward D. Ball, Moores University of California at San Diego Cancer Center, University of California, San Diego; John M. Timmerman and David Andorsky, University of California, Los Angeles, Los Angeles, CA; Joseph W. Fay, Baylor Research Institute, Baylor University Medical Center, Dallas; Chitra M. Hosing, The University of Texas MD Anderson Cancer Center, Houston, TX; David A. Rizzieri, Duke Cancer Center, Durham, NC; Joseph P. Uberti, Karmanos Cancer Institute, Detroit, MI; Markus Y. Mapara, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.48.3685
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.48.3685DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878008PMC
November 2013

Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.

Proc Natl Acad Sci U S A 2013 Jun 4;110(25):E2298-307. Epub 2013 Jun 4.

Cancer and Stem Cell Biology Program, Duke-National University of Singapore Graduate Medical School, Singapore 169857.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1301838110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3690864PMC
June 2013

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Proc Natl Acad Sci U S A 2013 Feb 16;110(6):2300-5. Epub 2013 Jan 16.

Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1206551110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568344PMC
February 2013

New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.

Int J Hematol Oncol 2013 Feb;2(1)

Division of Hematologic Malignancies & Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh.13.4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3841006PMC
February 2013

MDS: unraveling the mystery.

Authors:
David A Rizzieri

Blood 2012 Dec;120(25):4906-8

Duke Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-09-452755DOI Listing
December 2012

Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria.

Clin Adv Hematol Oncol 2012 Feb;10(2):136-7

Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
February 2012

Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.

Int J Radiat Oncol Biol Phys 2011 Nov 6;81(3):812-8. Epub 2010 Oct 6.

Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016100094
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2010.06.058DOI Listing
November 2011

Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Biol Blood Marrow Transplant 2011 Jun 22;17(6):867-74. Epub 2010 Sep 22.

Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2010.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877679PMC
June 2011

Alemtuzumab for the prevention and treatment of graft-versus-host disease.

Int J Hematol 2011 May 3;93(5):586-593. Epub 2011 Mar 3.

Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 1100, Durham, NC, 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-011-0802-2DOI Listing
May 2011

Haploidentical transplantation for leukemia.

Curr Oncol Rep 2010 Sep;12(5):292-301

Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-010-0113-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874937PMC
September 2010

Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

J Clin Oncol 2009 Nov 26;27(33):5580-6. Epub 2009 Oct 26.

Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27708, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.2547DOI Listing
November 2009

Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.

Cancer 2009 Jul;115(13):2922-9

Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24379DOI Listing
July 2009

Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.

Am J Hematol 2007 Dec;82(12):1063-70

Department of Medicine, Division of Hematology, VA and Duke University Medical Centers, 508 Fulton Street, Durham, North Carolina 27705, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.20987DOI Listing
December 2007

Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors.

Biol Blood Marrow Transplant 2007 Nov;13(11):1249-67

Adult Bone Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S108387910700383
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2007.08.003DOI Listing
November 2007

Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity.

Leuk Lymphoma 2005 Oct;46(10):1455-62

Department of Medicine, Division of Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190500158060DOI Listing
October 2005

Radioimmunotherapy for Non-Hodgkin's Lymphoma.

Clin Med Res 2005 Aug;3(3):157-65

Division of Medical Oncology and Division of Geriatrics, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1237157PMC
August 2005

Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.

Clin Cancer Res 2005 Jun;11(11):4225-33

North Carolina Central University and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-2106DOI Listing
June 2005

Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.

Clin Lymphoma 2004 Sep;5(2):116-22

Department of Medicine, Division of Medical Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
September 2004

Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.

Biol Blood Marrow Transplant 2004 Aug;10(8):569-75

Division of Cellular Therapy/BMT, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S108387910400244
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2004.05.001DOI Listing
August 2004

Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?

Chest 2004 Aug;126(2):642-4

Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1378/chest.126.2.642DOI Listing
August 2004

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.

Cancer 2004 Jun;100(11):2408-14

Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Network, Duke University, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.20245DOI Listing
June 2004

Rituximab in lymphocyte predominance Hodgkin's disease: a case series.

Clin Lymphoma 2003 Sep;4(2):115-8

Division of Medical Oncology and transplantation, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
September 2003

Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells.

Biol Blood Marrow Transplant 2002 ;8(5):249-56

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
July 2003

Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.

Clin Cancer Res 2003 Feb;9(2):663-8

Duke University Medical Center, Division of Medical Oncology and Transplantation and the Duke Oncology Consortium, Durham, North Carolina 27710, USA.

View Article

Download full-text PDF

Source
February 2003

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.

J Clin Oncol 2002 Jul;20(13):2995-3000

Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Consortium, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.08.166DOI Listing
July 2002

CD52 expression in mantle cell lymphoma.

Leuk Lymphoma 2002 Feb;43(2):339-42

Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190290006125DOI Listing
February 2002